Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
about
Bone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMAModeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Risk of osteoporosis and fracture incidence in patients on antipsychotic medication.Factors affecting hospital stay in psychiatric patients: the role of active comorbidity.Prevalence of osteopenia and osteoporosis and factors associated with decreased bone mineral density in elderly inpatients with psychiatric disorders in Huzhou, China.Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary studyThe evolution of hyperprolactinaemia as an entity in psychiatric patients.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemiaGender differences in schizophrenia and first-episode psychosis: a comprehensive literature review.Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.The Effects of Chlorpromazine on Reproductive System and Function in Female Rats.Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs.The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disordersOsteoporosis and fracture risk in people with schizophreniaAffective Disorders, Bone Metabolism, and Osteoporosis.Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment.Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder.Teratogenicity and hyperprolactinemia.Risk of venous thromboembolism due to antipsychotic drug therapy.Prolactin and psychopathology in schizophrenia: a literature review and reappraisalRisperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder.Hypoestrogenism in young women and its influence on bone mass density.Antipsychotic-induced hyperprolactinaemia.Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.Use of asenapine in clinical practice for the management of bipolar mania.Management of schizophrenia: clinical experience with asenapine.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications.An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.Preventing breast cancer in women with schizophrenia.Relationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia
P2860
Q26775158-8B182972-5055-4595-947D-5559A4E6FF50Q33526671-13A5E516-42AF-4E66-8257-0135CC9C657CQ33619940-7DC4CCFE-47F6-45B9-A431-9EC45FD80D13Q34026011-D840E042-B3D6-48FC-A66F-B17C03B23DCAQ34309209-C73DF571-9901-478B-8E2E-19F9B9B0EDA0Q34347472-349D8DE1-87E8-4523-AB55-E6AC246616A6Q34497563-EFBD915E-0591-4160-A50E-F42DCD269705Q34591930-F2C1F47B-94DB-48A9-ACB4-861319E4D10EQ34623350-CBFE5EF9-4488-4763-A28F-65A0DE424390Q34966395-06B35298-7939-4CC4-847E-80929903686EQ35167958-33025F95-5B47-4305-A890-75D3626E8326Q36168604-D5FA04FA-E9B9-41E4-B80E-1A8541F98990Q36188000-D12AB190-F369-44D9-B119-507D792B6653Q36351299-E325393B-EB53-4A49-A121-FF98A60D9AC2Q36431173-EF64DC7C-4C70-45DF-9770-DBC71D239BDFQ36570221-051340D9-1FF3-44D7-BD84-C83846AEE15BQ36592205-F3A255BF-5B9C-4F8E-BE70-7ECD96524610Q37027277-862B2092-F820-4E04-9DF5-245BF4E2178FQ37078982-11F51AB5-340A-4D36-87C5-60692D662C3EQ37162812-1B725B4C-EE87-47B2-B576-F63DACA80B90Q37334220-1AF098B7-53F5-43EC-9434-FA254E8EE8DEQ37537576-81E8BE71-53D4-47C3-8C8D-3C59794EAEF6Q37700747-BC9D0374-8FE7-4D80-B98B-C26763D44442Q37756971-4D0B370B-12C0-44DB-8FC4-A421991F60B4Q37760937-397B1BDF-6BB3-490E-B873-977F6576F5F3Q37895702-846CD43F-B620-4235-9379-973C3CA6B295Q37999566-344DF8A4-7699-4880-A66A-315A6E5E516BQ38021516-1AE6A004-218B-4F9C-AEAA-4ACFE855B511Q38093728-EBCC0027-8001-41A9-8275-D54F2026D2F3Q38093729-19212028-5596-4CCD-A820-2A8D74E580E4Q38778145-5F16CC0F-C2C2-4C9A-831B-E19A4ABBB9AFQ47350555-572FD3C8-1398-4C9E-98C9-90835291B586Q47555827-C8BE3629-79A8-4E17-BC4A-955CA8BD6904Q48908840-AA7A54BD-8F44-41C5-843F-315FADAE4DB2Q51832889-267DC29C-D5FC-431F-9103-6C990195EAC5Q57820223-9EA77829-89B1-4FE8-B03C-99CB709D76C2
P2860
Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antipsychotic-induced hyperpro ...... he treatment of schizophrenia.
@en
Antipsychotic-induced hyperpro ...... he treatment of schizophrenia.
@nl
type
label
Antipsychotic-induced hyperpro ...... he treatment of schizophrenia.
@en
Antipsychotic-induced hyperpro ...... he treatment of schizophrenia.
@nl
prefLabel
Antipsychotic-induced hyperpro ...... he treatment of schizophrenia.
@en
Antipsychotic-induced hyperpro ...... he treatment of schizophrenia.
@nl
P2860
P921
P356
P1476
Antipsychotic-induced hyperpro ...... he treatment of schizophrenia.
@en
P2860
P356
10.1177/0269881107088439
P407
P433
P577
2008-03-01T00:00:00Z